PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 20432447-2 2010 This study shows that restriction of tyrosine and phenylalanine (Tyr/Phe), glutamine (Gln), or methionine (Met) differentially modulates glucose metabolism, glycogen synthase kinase 3beta (GSK3beta), p53, and pyruvate dehydrogenase (PDH) in these two cell lines. Tyrosine 37-45 tumor protein p53 Homo sapiens 200-203 20432447-2 2010 This study shows that restriction of tyrosine and phenylalanine (Tyr/Phe), glutamine (Gln), or methionine (Met) differentially modulates glucose metabolism, glycogen synthase kinase 3beta (GSK3beta), p53, and pyruvate dehydrogenase (PDH) in these two cell lines. Tyrosine 65-68 tumor protein p53 Homo sapiens 200-203 20499882-0 2010 Nitration of the tumor suppressor protein p53 at tyrosine 327 promotes p53 oligomerization and activation. Tyrosine 49-57 tumor protein p53 Homo sapiens 42-45 20432447-6 2010 Tyr/Phe, Gln and Met restriction increase phosphorylation of GSK3beta-Ser(9), phosphorylation of p53-Ser(15) and reduce the mitochondrial localization of PDH. Tyrosine 0-3 tumor protein p53 Homo sapiens 97-100 20432447-8 2010 In p53-null PC3 cells, Tyr/Phe, Gln and Met restriction decreases glucose consumption, reduces phosphorylation of Akt-Ser(473), and increases phosphorylation of GSK3beta-Ser(9). Tyrosine 23-26 tumor protein p53 Homo sapiens 3-6 20499882-0 2010 Nitration of the tumor suppressor protein p53 at tyrosine 327 promotes p53 oligomerization and activation. Tyrosine 49-57 tumor protein p53 Homo sapiens 71-74 19075013-9 2009 One of these phosphorylations, on tyrosine 99, inhibited Hdmx interaction with p53. Tyrosine 34-42 tumor protein p53 Homo sapiens 79-82 20395957-6 2010 Our findings demonstrate that (i) PKR, Ser/Thr kinase, phosphorylates its new substrate Cdc2 at the Tyr 4 residue, (ii) PKR-mediated Tyr 4-phosphorylation facilitates Cdc2 ubiquitination and proteosomal degradation, (iii) unphosphorylated Tyr 4 prevents Cdc2 ubiquitination, and (iv) downstream from p53, PKR has a crucial role in G2 arrest and triggers Cdc2 downregulation under genotoxic conditions. Tyrosine 100-103 tumor protein p53 Homo sapiens 300-303 20395957-6 2010 Our findings demonstrate that (i) PKR, Ser/Thr kinase, phosphorylates its new substrate Cdc2 at the Tyr 4 residue, (ii) PKR-mediated Tyr 4-phosphorylation facilitates Cdc2 ubiquitination and proteosomal degradation, (iii) unphosphorylated Tyr 4 prevents Cdc2 ubiquitination, and (iv) downstream from p53, PKR has a crucial role in G2 arrest and triggers Cdc2 downregulation under genotoxic conditions. Tyrosine 133-136 tumor protein p53 Homo sapiens 300-303 20395957-6 2010 Our findings demonstrate that (i) PKR, Ser/Thr kinase, phosphorylates its new substrate Cdc2 at the Tyr 4 residue, (ii) PKR-mediated Tyr 4-phosphorylation facilitates Cdc2 ubiquitination and proteosomal degradation, (iii) unphosphorylated Tyr 4 prevents Cdc2 ubiquitination, and (iv) downstream from p53, PKR has a crucial role in G2 arrest and triggers Cdc2 downregulation under genotoxic conditions. Tyrosine 133-136 tumor protein p53 Homo sapiens 300-303 19749791-0 2009 Repression of SHP-1 expression by p53 leads to trkA tyrosine phosphorylation and suppression of breast cancer cell proliferation. Tyrosine 52-60 tumor protein p53 Homo sapiens 34-37 19749791-3 2009 p53 can induce trkA activation and tyrosine phosphorylation in the absence of NGF stimulation. Tyrosine 35-43 tumor protein p53 Homo sapiens 0-3 18707164-3 2008 The specific residues of MDM2 that have dominant binding interactions with p53 are specifically identified to be (51)Lys, (54)Leu, (62)Met, (67)Tyr, (72)Gln, (94)Lys, (96)His, and (100)Tyr. Tyrosine 144-147 tumor protein p53 Homo sapiens 75-78 19101993-3 2009 Genetic analysis showed a germline TP53 mutation in codon 220 exon 6, which changed TAT --> TGT and resulted in a tyrosine-to-cysteine amino acid substitution (Tyr220Cys). Tyrosine 114-122 tumor protein p53 Homo sapiens 35-39 18707164-3 2008 The specific residues of MDM2 that have dominant binding interactions with p53 are specifically identified to be (51)Lys, (54)Leu, (62)Met, (67)Tyr, (72)Gln, (94)Lys, (96)His, and (100)Tyr. Tyrosine 185-188 tumor protein p53 Homo sapiens 75-78 16085052-2 2005 The mechanism underlying this tyrosine phosphorylation is thought to involve the sequential action of two protein tyrosine kinases, Syk (p72syk) and Lyn (p53/56lyn). Tyrosine 30-38 tumor protein p53 Homo sapiens 154-157 16700548-8 2006 On the basis of the comparison of the NQO1 structure in complex with different NQO1 inhibitors and our previous analysis of NQO1 mutants, we propose that the specific conformation of Tyr 128 and Phe 232 is important for NQO1 interaction with p53 and other client proteins. Tyrosine 183-186 tumor protein p53 Homo sapiens 242-245 15985438-3 2005 Expression of the ErbB-4 ICD fragment leads to its constitutive association with Mdm2 and tyrosine phosphorylation of Mdm2, a protein that is predominantly localized in the nucleus and that regulates p53 levels. Tyrosine 90-98 tumor protein p53 Homo sapiens 200-203 18791269-6 2008 In DB-1 melanoma cells that overexpress tyrosinase (Tyr(+) cells), the threshold for phosphorylation of ATM and p53 at serine 15 was observed at a low dose of Qct (25 microM) when compared to the mock transfected pcDNA3 cells, which required a higher dose (75 microM). Tyrosine 52-55 tumor protein p53 Homo sapiens 112-115 18791269-7 2008 Both pcDNA3 and Tyr(+) DB-1 cells demonstrated similar increases in phosphorylation of p53 at other serine sites, but in the Tyr(+) cells, DNApk expression was found to be reduced compared to control cells, indicating a shift towards an ATM-mediated response. Tyrosine 16-19 tumor protein p53 Homo sapiens 87-90 17938582-4 2007 The structure reveals that although the principle features of the Mdm2-p53 interaction are preserved in the Mdmx-p53 complex, the Mdmx hydrophobic cleft on which the p53 peptide binds is significantly altered: a part of the cleft is blocked by sidechains of Met and Tyr of the p53-binding pocket of Mdmx. Tyrosine 266-269 tumor protein p53 Homo sapiens 113-116 17938582-4 2007 The structure reveals that although the principle features of the Mdm2-p53 interaction are preserved in the Mdmx-p53 complex, the Mdmx hydrophobic cleft on which the p53 peptide binds is significantly altered: a part of the cleft is blocked by sidechains of Met and Tyr of the p53-binding pocket of Mdmx. Tyrosine 266-269 tumor protein p53 Homo sapiens 113-116 17938582-4 2007 The structure reveals that although the principle features of the Mdm2-p53 interaction are preserved in the Mdmx-p53 complex, the Mdmx hydrophobic cleft on which the p53 peptide binds is significantly altered: a part of the cleft is blocked by sidechains of Met and Tyr of the p53-binding pocket of Mdmx. Tyrosine 266-269 tumor protein p53 Homo sapiens 113-116 17070096-7 2007 Mutational analysis of p53 gene revealed an A-->G transition at the second base of codon 220, resulting in amino acid substitution from tyrosine to cysteine in the protein. Tyrosine 139-147 tumor protein p53 Homo sapiens 23-26 16219768-0 2005 WOX1 is essential for tumor necrosis factor-, UV light-, staurosporine-, and p53-mediated cell death, and its tyrosine 33-phosphorylated form binds and stabilizes serine 46-phosphorylated p53. Tyrosine 110-118 tumor protein p53 Homo sapiens 188-191 15615778-3 2005 The p53-independent pathway involves a phosphorylation cascade that activates the Chk1 effector kinase and induces G2 arrest through inhibitory tyrosine phosphorylation of Cdc2. Tyrosine 144-152 tumor protein p53 Homo sapiens 4-7 15888975-8 2005 This mutation causes an amino-acid replacement (Tyr to Cys), which was previously proven to attenuate p53 function. Tyrosine 48-51 tumor protein p53 Homo sapiens 102-105 15849679-3 2005 One of the mechanisms of tumoural progression consists in the protein inactivation resulting from the NO nitration of tyrosine from proteins coded for by tumour-suppressing genes, such as p53. Tyrosine 118-126 tumor protein p53 Homo sapiens 188-191 12082540-3 2002 Our results demonstrate that expression of wt p53 but not mutant p53 significantly reduced tyrosine phosphorylation of Stat3 and inhibited Stat3 DNA binding activity in both DU145 and Tsu prostate cancer cell lines that express constitutively active Stat3. Tyrosine 91-99 tumor protein p53 Homo sapiens 46-49 15358195-5 2004 Expression of wt p53, but not that of p53-175 mutant, diminished JAK2 tyrosine phosphorylation in MDAH2774 and Caov-3 cell lines. Tyrosine 70-78 tumor protein p53 Homo sapiens 17-20 15358195-9 2004 These findings present a possible p53-dependent cellular process of modulating JAK2 tyrosine phosphorylation in ovarian cancer cell lines. Tyrosine 84-92 tumor protein p53 Homo sapiens 34-37 12682067-5 2003 At one subunit interface of AChBP, the side chain of Tyr-89 closely approaches a positively charged nitrogen in d-TC but is farther away from the equivalent nitrogen in metocurine, whereas, at the opposing interface, side chains of Trp-53 and Gln-55 closely approach the metocurine scaffold but not that of d-TC. Tyrosine 53-56 tumor protein p53 Homo sapiens 232-238 12110584-0 2002 Tyrosine phosphorylation of Mdm2 by c-Abl: implications for p53 regulation. Tyrosine 0-8 tumor protein p53 Homo sapiens 60-63 10631110-0 2000 Nitric oxide nitrates tyrosine residues of tumor-suppressor p53 protein in MCF-7 cells. Tyrosine 22-30 tumor protein p53 Homo sapiens 60-63 11841447-7 2002 We found that the expression of the cell cycle checkpoint protein Chk1 was reduced in the etoposide-treated p53-transfected cells by 24 h, and this correlated with a reduction in the extent of etoposide-induced phosphorylation of CDK1 at tyrosine 15 (Y15). Tyrosine 238-246 tumor protein p53 Homo sapiens 108-111 11423998-6 2001 Tyrosine-phosphorylation of p53/p46Shc isoforms were found in CD34+ but not in the majority of CD34- cases. Tyrosine 0-8 tumor protein p53 Homo sapiens 28-31 11594730-4 2001 Experiments in vitro demonstrate that peroxynitrite treatment of recombinant wild-type p53 at physiological concentrations results in formation of higher molecular weight aggregates, tyrosine nitration, and loss of specific DNA binding. Tyrosine 183-191 tumor protein p53 Homo sapiens 87-90 11594730-5 2001 Peroxynitrite treatment of human glioma cell lysates similarly resulted in selective tyrosine nitration of p53 and was also associated with loss of p53 DNA binding ability. Tyrosine 85-93 tumor protein p53 Homo sapiens 107-110 10693987-10 2000 Four of the five mutations in the p53 antibody-positive patients affected a Tyr residue, whereas none of the gene abnormalities in the seronegative patients had such an effect. Tyrosine 76-79 tumor protein p53 Homo sapiens 34-37 10693987-12 2000 Further, p53 antibody-positive patients do not have higher frequency of p53 gene mutations than p53 antibody-negative patients, but the former patient group is associated with a Tyr substitution in the protein product. Tyrosine 178-181 tumor protein p53 Homo sapiens 9-12 10631110-2 2000 As nitration of tyrosine residues in various proteins has been shown to inhibit their functions, we examined whether NO nitrates tyrosine residues in p53 protein. Tyrosine 129-137 tumor protein p53 Homo sapiens 150-153 8647200-2 1996 Engagement of CD22 with a monoclonal antibody (HB22.23) that blocks the binding of CD22 to its ligands results in rapid CD22 tyrosine phosphorylation and in increased association of CD22 with p53/56lyn kinase, p85 phosphatidyl inositol-3 kinase, and p72syk kinase. Tyrosine 125-133 tumor protein p53 Homo sapiens 192-195 10087941-9 1999 Homozygous deletion in p16INK4A/p15INK4B genes and a codon 259 missense point mutation (GAC-->TAC; Asp-->Tyr) in the TP53 gene were observed in one human papilloma positive scrotal carcinoma case. Tyrosine 111-114 tumor protein p53 Homo sapiens 123-127 9931317-6 1999 After stimulation by CRP or collagen, the Src-family kinases p59fyn and p53/56lyn became associated with several tyrosine-phosphorylated proteins including the FcR gamma chain. Tyrosine 113-121 tumor protein p53 Homo sapiens 72-75 9796399-8 1998 Analysis of the p53 gene by the polymerase chain reaction-single strand conformation polymorphism method showed one base transposition, from TAT to TGT (Tyr to Cys), at codon 220 of exon 6. Tyrosine 153-156 tumor protein p53 Homo sapiens 16-19 9492043-5 1998 Similarly, wild-type p53 decreased IGF-I-induced tyrosine phosphorylation of IRS-1. Tyrosine 49-57 tumor protein p53 Homo sapiens 21-24 9492043-10 1998 In conclusion, p53 regulates IGF-IR expression, as reflected by a reduction in IGF-IR protein and a parallel reduction in IGF-I-induced tyrosine phosphorylation of the IGF-IR and IRS-1 in an osteosarcoma cell line. Tyrosine 136-144 tumor protein p53 Homo sapiens 15-18 9083038-6 1997 We show that cross-linking of ICAM-1 on the B lymphoma line A20 induces an increase in tyrosine phosphorylation of several cellular proteins, including the Src family kinase p53/p56(lyn). Tyrosine 87-95 tumor protein p53 Homo sapiens 174-177 8985154-2 1996 The two alternative forms of Lyn (p53 and p56) were found to be tyrosine-phosphorylated within 30 s after the stimulation with acetyl LDL. Tyrosine 64-72 tumor protein p53 Homo sapiens 34-37 9038605-4 1996 In 4 cases, the mutations lead to distinct changes in the primary or secondary structure of the protein (cysteine-->tyrosine, proline-->leucine) and were associated with marked accumulation of p53 protein. Tyrosine 119-127 tumor protein p53 Homo sapiens 199-202 9182295-5 1996 Single strand conformation polymorphism analysis (SSCP-PCR) from DNA obtained by microdissection demonstrated the presence of a mutation (TAT-->TGT; Tyr-->Cys) in codon 220, exon six of the p53 gene in the anaplastic component, that was absent in the well-differentiated follicular areas. Tyrosine 152-155 tumor protein p53 Homo sapiens 196-199 9796924-6 1998 Triggering of sIg induced, within seconds, identical tyrosine phosphorylation of p53/56lyn protein tyrosine kinase (PTK) and p55blk PTK in both of the cell lines; however, a prominent tyrosine phosphorylation and activation of p72syk PTK only in HF-1.3.4 cells. Tyrosine 53-61 tumor protein p53 Homo sapiens 81-84 9796924-6 1998 Triggering of sIg induced, within seconds, identical tyrosine phosphorylation of p53/56lyn protein tyrosine kinase (PTK) and p55blk PTK in both of the cell lines; however, a prominent tyrosine phosphorylation and activation of p72syk PTK only in HF-1.3.4 cells. Tyrosine 99-107 tumor protein p53 Homo sapiens 81-84 9492043-0 1998 p53 regulates insulin-like growth factor-I (IGF-I) receptor expression and IGF-I-induced tyrosine phosphorylation in an osteosarcoma cell line: interaction between p53 and Sp1. Tyrosine 89-97 tumor protein p53 Homo sapiens 0-3 8798554-11 1996 Tyrosine phosphorylation of proteins in adherent, CGD neutrophils was only partially inhibited, suggesting that the full activation of p58(c-fgr) and p53/56(lyn), which depends on endogenously produced ROI, does not represent an absolute requirement for protein tyrosine phosphorylation. Tyrosine 0-8 tumor protein p53 Homo sapiens 150-153 8665492-3 1996 Only 1/45 samples showed the incidence of a homozygous mutation at codon 179 (exon 5) of the p53 gene that replaces histidine with tyrosine. Tyrosine 131-139 tumor protein p53 Homo sapiens 93-96 7478539-0 1995 UREB1, a tyrosine phosphorylated nuclear protein, inhibits p53 transactivation. Tyrosine 9-17 tumor protein p53 Homo sapiens 59-62 8603737-5 1996 These changes of p58c-fgr and p53/56lyn distribution and activity correlate with tyrosine phosphorylation of endogenous substrates. Tyrosine 81-89 tumor protein p53 Homo sapiens 30-33 7478539-7 1995 These data suggest that optimal suppression of p53 transactivation requires tyrosine phosphorylated UREB1 and that tyrosine phosphorylation and dephosphorylation processes may be involved in the regulation of p53 transactivation. Tyrosine 76-84 tumor protein p53 Homo sapiens 47-50 7478539-7 1995 These data suggest that optimal suppression of p53 transactivation requires tyrosine phosphorylated UREB1 and that tyrosine phosphorylation and dephosphorylation processes may be involved in the regulation of p53 transactivation. Tyrosine 115-123 tumor protein p53 Homo sapiens 209-212 7597296-5 1995 Analysis of p53 gene showed mutation only in one case of mycosis fungoides in tumoral stage, at codon 163 of p53 gene (TAC-->CAC; Tyr--> Asp). Tyrosine 133-136 tumor protein p53 Homo sapiens 12-15 7897229-10 1995 Third, p53-56lyn was probably activated after cell stimulation with zymosan, because the phosphorylation levels of a synthetic copolymer of glutamine-tyrosine were increased in Triton X-100-insoluble fraction. Tyrosine 150-158 tumor protein p53 Homo sapiens 7-10 7597296-5 1995 Analysis of p53 gene showed mutation only in one case of mycosis fungoides in tumoral stage, at codon 163 of p53 gene (TAC-->CAC; Tyr--> Asp). Tyrosine 133-136 tumor protein p53 Homo sapiens 109-112 15335855-6 1993 Furthermore, crosslinking of the chimeras resulted in tyrosine phosphorylation of the Ig-alpha and Tg-beta tails and their association with the tyrosine kinases PTK72, p53/56(lyn) and p59(fyn). Tyrosine 54-62 tumor protein p53 Homo sapiens 168-171 8278402-4 1994 Mutant p53 fusion proteins carrying amino acid substitutions Glu-213, Ile-237, or Tyr-238, derived from mutant p53 genes of Burkitt lymphomas, failed to catalyze these reactions. Tyrosine 82-85 tumor protein p53 Homo sapiens 7-10 7787250-9 1994 The T24 cell line was found to contain a novel p53 mutant having an in-frame deletion of tyrosine 126. Tyrosine 89-97 tumor protein p53 Homo sapiens 47-50 8375929-4 1993 The IGF-I-induced DNA synthesis coincided with an elevated level of phosphorylation of p53 on tyrosine and an alteration in the subcellular distribution of the protein from the nucleus to the cytoplasm. Tyrosine 94-102 tumor protein p53 Homo sapiens 87-90 33777934-7 2021 The regular dephosphorylation of NPM"s tyrosines by DUSP3 balances the p53 functioning and favors the repair of UV-promoted DNA lesions needed for the maintenance of genomic stability. Tyrosine 39-48 tumor protein p53 Homo sapiens 71-74 8389256-6 1993 The p53 point mutations in the three HCC cell lines from Japan resulted in the amino acid changes of cysteine for tyrosine in cell line HuH 7 at codon 220 (A:T-->G:C), alanine for glycine in cell line HLF at codon 244 (G:C-->C:G), and serine for arginine in cell line HLE at codon 249 (G:C-->C:G). Tyrosine 114-122 tumor protein p53 Homo sapiens 4-7 1506270-3 1992 Immunoprecipitation analysis revealed that mutant p53 was phosphorylated at tyrosine in the anchorage-provided cells. Tyrosine 76-84 tumor protein p53 Homo sapiens 50-53 1506270-6 1992 These results demonstrated that the growth inhibition by anchorage-deficiency or by herbimycin A is associated with an elevated p53 level and reduced p53 phosphorylation at tyrosine. Tyrosine 173-181 tumor protein p53 Homo sapiens 150-153 33326188-4 2021 Therefore, a CD44-targeted delivery system is designed and constructed by self-assembly of tyrosine (Tyr)-hyaluronic acid (HA)-polyethyleneimine (PEI), which can radiolabel 131/125 I and load a p53 mutant restoring regent, Prima-1. Tyrosine 91-99 tumor protein p53 Homo sapiens 194-197 32561851-0 2020 NEK10 tyrosine phosphorylates p53 and controls its transcriptional activity. Tyrosine 6-14 tumor protein p53 Homo sapiens 30-33 32561851-4 2020 Here, we describe a function for NEK10 in the regulation of p53 transcriptional activity through tyrosine phosphorylation. Tyrosine 97-105 tumor protein p53 Homo sapiens 60-63 31984217-4 2019 More recently, we demonstrated that the SRC family of non-receptor tyrosine kinases (SFK) can phosphorylate SOCS1 leading to its homodimerization and inhibiting its interaction with p53. Tyrosine 67-75 tumor protein p53 Homo sapiens 182-185 32023774-0 2020 [The influence of TP53 mutation on the therapeutic effect of EGFR tyrosine kinase inhibitor and prognosis of EGFR mutant non-small cell lung cancer patients]. Tyrosine 66-74 tumor protein p53 Homo sapiens 18-22 30633343-10 2019 KEGG analysis results showed that DEGs were particularly enriched in the cell cycle, the p53 signaling pathway, the Wnt signaling pathway, the Ras signaling pathway, the Rap1 signaling pathway, and tyrosine metabolism. Tyrosine 198-206 tumor protein p53 Homo sapiens 89-92 31101761-3 2019 We report here that the ability of SOCS1 to interact with p53 and regulate cellular senescence depends on a structural motif that includes tyrosine (Y)80 in the SH2 domain of SOCS1. Tyrosine 139-147 tumor protein p53 Homo sapiens 58-61 30910997-4 2019 DYRK1A (dual-specificity tyrosine-phosphorylated and tyrosine-regulated kinase 1A), an EGFR-stabilizing kinase, is downregulated by p53 and, when ectopically expressed, can attenuate p53 activation-induced EGFR reduction and cellular senescence. Tyrosine 25-33 tumor protein p53 Homo sapiens 132-135 30910997-4 2019 DYRK1A (dual-specificity tyrosine-phosphorylated and tyrosine-regulated kinase 1A), an EGFR-stabilizing kinase, is downregulated by p53 and, when ectopically expressed, can attenuate p53 activation-induced EGFR reduction and cellular senescence. Tyrosine 25-33 tumor protein p53 Homo sapiens 183-186 27385486-5 2016 Herein, we report that GOF mutant R175H and R273H p53 proteins trigger PKM2 phosphorylation on Tyr 105 through the involvement of mTOR signaling. Tyrosine 95-98 tumor protein p53 Homo sapiens 50-53 29853637-6 2018 Fluorescence experiments revealed conformational changes of the single Trp and Tyr residues before p53 unfolding and the presence of MG conformers, some of which were highly prone to aggregation. Tyrosine 79-82 tumor protein p53 Homo sapiens 99-102 29431732-5 2018 Specifically, blocking AhR redirected IFN-beta signaling to STAT3 phosphorylation through both tyrosine and serine sites, which subsequently facilitated STAT3 nuclear translocation and subsequent binding to the p53 promoter in the nucleus. Tyrosine 95-103 tumor protein p53 Homo sapiens 211-214 26520021-8 2015 The support l-tyrosine Sepharose used in chromatographic experiments promotes the separation of native pVAX1-LacZ and pcDNA3-FLAG-p53 samples (oc+sc) by decreasing the salt concentration. Tyrosine 12-22 tumor protein p53 Homo sapiens 130-133 21734451-5 2011 It can trigger G 2/M arrest in wild type p53 containing cells, which was attributed to the decreased Cdc2 kinase activity resulting at least partly from a high level of inhibitory tyrosine phosphorylation on Cdc2 protein at Tyr-15. Tyrosine 180-188 tumor protein p53 Homo sapiens 41-44 23874455-4 2013 Pharmacologic targeting of STAT3 expression in cervical cancer cell lines either by STAT3-specific siRNA or blocking its tyrosine phosphorylation by AG490 or curcumin led to dose-dependent accumulation of p53 and pRb in cervical cancer cells. Tyrosine 121-129 tumor protein p53 Homo sapiens 205-208 27481281-7 2013 It was found that the pi-pi stacking between Tyr 51 of MDM2 and ligands is the critical event in MDM2-p53 dissociation. Tyrosine 45-48 tumor protein p53 Homo sapiens 102-105 24833526-9 2014 We further demonstrate that an activation of the oncologically relevant transcription factor p53 in lung cancer cells induces SIAH2, depletes TYK2, and abrogates the tyrosine phosphorylation of STAT1 and STAT3. Tyrosine 166-174 tumor protein p53 Homo sapiens 93-96 21734451-5 2011 It can trigger G 2/M arrest in wild type p53 containing cells, which was attributed to the decreased Cdc2 kinase activity resulting at least partly from a high level of inhibitory tyrosine phosphorylation on Cdc2 protein at Tyr-15. Tyrosine 224-227 tumor protein p53 Homo sapiens 41-44 21465572-2 2011 In response to oxidative, nitrosative, and electrophilic insults, p53 undergoes post-translational modifications, such as oxidation and covalent modification of cysteines, nitration of tyrosines, acetylation of lysines, phosphorylation of serine/threonine residues, etc. Tyrosine 185-194 tumor protein p53 Homo sapiens 66-69 21398698-4 2011 DDR1 is functionally activated as determined by its tyrosine phosphorylation, in response to p53-dependent DNA damage. Tyrosine 52-60 tumor protein p53 Homo sapiens 93-96